Storia in 2 fonti

Strides Pharma sells majority stake in arm Pivot Path for ₹100 cr

Strides Pharma divests majority stake in Pivot Path for ₹100 crore, retaining 19.95% and enabling growth through strategic investment.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo4 g fa

Strides Pharma sells majority stake in arm Pivot Path for ₹100 cr

Strides Pharma divests Pivot Path to Ascent Capital for ₹100 crore (₹230 crore post-money valuation). Pharma consolidating AI-driven compliance and digital transformation outsourcing; Pivot Path's 400+ SMEs and Agentic-AI target regulated sectors' market demand.

originale

economictimes.indiatimes.com4 g fa

Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore

Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth…

Leggi questa versione → originale

Timeline cronologica

sabato 27 giugno 2026·economictimes.indiatimes.com
Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore
Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move…
domenica 28 giugno 2026·thehindubusinessline.com
Strides Pharma sells majority stake in arm Pivot Path for ₹100 cr
Strides Pharma divests majority stake in Pivot Path for ₹100 crore, retaining 19.95% and enabling growth through strategic investment.